A Phase 2 interventional study of RO7965032 and Placebo in Geographic Atrophy Secondary to Age-Related Macular Degeneration, sponsored by Genentech, Inc.. Recruiting at 5 sites in United States. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2026-10-26.
Sponsored by Genentech, Inc. (part of Hoffmann-La Roche) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 16 studies in Geographic Atrophy by Hoffmann-La Roche — 2 open to participants now, 2 under way, none of them phase 3. Geographic Atrophy · Hoffmann-La Roche.
Among the 16 studies in Geographic Atrophy by Hoffmann-La Roche, this one is the 5th largest by planned enrollment of the 14 interventional ones that give a count, is the only one that started in 2027, is one of 7 in phase 2, and was the 16th registered.
188 studies on the registry are indexed under Geographic Atrophy; 52 are open to participants now.
Browse Geographic Atrophy studies →2 of the 16 studies in Geographic Atrophy by Hoffmann-La Roche are open now, in 2 countries. Recruiting first, the newest first:
Genentech, Inc. · Sites in United States, Israel
Ages 50+
By country, each count listing its studies:
Of the 40 Geographic Atrophy studies recruiting now, 31 (78%) set no upper age limit and none (0%) stop at 75 or younger; 2 take children under 18; 4 take healthy volunteers.
This study: 50 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
16 studies; the count open now beside each. This study's row is marked.
First in 2009; this study’s year is marked. 1 started in 2027.
This study's planned enrollment of 321 is above the median of 70 across 141 interventional studies indexed under Geographic Atrophy.
Median enrollment 144 across the 14 interventional studies, 249 across the 2 observational. Of the 14 that completed or were terminated, 7 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Genentech, Inc., one of the names counted as Hoffmann-La Roche. Under that name alone:
Genentech, Inc. is the lead sponsor of 517 studies on the registry; 20 are open to participants now.
Of its 95 completed or terminated interventional studies of FDA-regulated products, 52 (55%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 16 studies in Geographic Atrophy by Hoffmann-La Roche, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study will assess the safety and efficacy of RO7965032 to address a significant unmet medical need in participants with geographic atrophy (GA) secondary to age-related macular degeneration (AMD)
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Ocular Inclusion Criteria for the Study Eye
Ocular Inclusion Criteria for Both Eyes
Exclusion Criteria:
General Exclusion Criteria - History of , a severe allergic reaction or anaphylactic reaction to any component of the drug injection
Ocular Exclusion Criteria for the Study Eye
Ocular Exclusion Criteria for the Non-Study Eye
- Non-functioning non-study eye defined as either BCVA of hand motion or worse or no physical presence of non-study eye (i.e., monocular)
Ocular Exclusion Criteria for Either Eye
Other protocol-defined inclusion/exclusion criteria may apply
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive RO7965032.
Drug: RO7965032
Participants will receive RO7965032.
Drug: RO7965032
Participants will receive placebo.
Drug: Placebo
RO7965032 will be administered as per the schedule defined in the protocol.
Placebo will be administered as per the schedule defined in the protocol.
Change of GA Lesion Area in the Study Eye
Time frame: Baseline up to approximately 48 weeks
Incidence and Severity of Ocular Adverse Events (AEs)
Time frame: Up to approximately 72 Weeks
Incidence and Severity of Non-Ocular AEs
Time frame: Up to approximately 72 Weeks
Change of GA Lesion Area in the Study Eye
Time frame: Baseline up to approximately 72 weeks
Change from Baseline in Best Correct Visual Acuity (BCVA) Score on the Early Treatment Diabetic Retinopathy Study (ETDRS) Chart
Time frame: Baseline up to approximately 48 weeks
Change from Baseline in BCVA Score on the ETDRS Chart Under Low-luminance Conditions
Time frame: Baseline up to approximately 48 weeks
Incidence and Severity of Selected Findings in Ocular Examinations and Ocular Imaging
Time frame: Up to approximately 72 Weeks
Plasma Concentration of RO7965032
Time frame: Baseline up to approximately 72 weeks
Percent Change from Baseline in Levels of Target Protein in Plasma
Time frame: Baseline up to approximately 72 weeks
Percent Change from Baseline in Levels of Plasma Biomarker Activity
Time frame: Baseline up to approximately 72 weeks
Prevalence and Incidence of Anti-Drug Antibodies (ADAs)
Time frame: Baseline up to approximately 72 weeks
Recommended Dose of RO7965032
Time frame: Up to approximately 72 Weeks
Plan to share: Yes — For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data_sharing
No publications or documents are linked to this record.
Start is estimated for Jan 2027; primary completion for Aug 2030, 43 months later.
Of 24 phase 2 interventional studies under Geographic Atrophy, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 54. This study's planned 43 months is above that.
Start moved once since we started tracking on Sep 25, 2026: Sep 2026 → Jan 2027, on Oct 26, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.